<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196023</url>
  </required_header>
  <id_info>
    <org_study_id>100106a</org_study_id>
    <nct_id>NCT04196023</nct_id>
  </id_info>
  <brief_title>Ca:Mg Ratio and Cognitive Function</brief_title>
  <official_title>Ca:Mg Ratio and Cognitive Function in the Personalized Prevention of Colorectal Cancer Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 2000 and 2015, mortality due to Alzheimer's disease (AD) increased by 123%. No drugs&#xD;
      have yet been approved to stop or slow the progression of AD. A delay of five years in the&#xD;
      expression of AD would reduce the incidence rate by half. Thus, it is critical to develop&#xD;
      novel prevention strategies to delay the onset of this common disease.&#xD;
&#xD;
      As an ancillary study conducted within a precision-based randomized trial (R01CA149633; PI,&#xD;
      Dai &amp; Yu]&quot;), the investigators reduced Ca:Mg ratios to 2.3 through 3-month personalized Mg&#xD;
      supplementation among those who consumed high Ca:Mg ratio diet, but otherwise in good general&#xD;
      health. The investigators test the hypothesis that actively reducing the Ca:Mg ratio among&#xD;
      those aged &gt;65 years who consume high Ca:Mg ratio diets improves cognitive function compared&#xD;
      to the placebo arm. The investigators further conduct molecular epidemiologic studies to&#xD;
      understand the molecular mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2012</start_date>
  <completion_date type="Anticipated">December 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cognitive function was measured by the Montreal Cognitive Assessment (MoCA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>APOE Cytosine Modifications</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Cognitive Function</condition>
  <arm_group>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GG genotype and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium glycinate</intervention_name>
    <description>Oral administration of magnesium glycinate daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of identical-appearing placebo daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_label>GG genotype and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants from our parent study (Personalized Prevention of Colorectal Cancer&#xD;
             Trial, NCT#01105169, IRB#100106);&#xD;
&#xD;
          2. Participants who completed the MoCA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Participants did not provide their blood samples in the parent study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Zhu X, Borenstein AR, Zheng Y, Zhang W, Seidner DL, Ness R, Murff HJ, Li B, Shrubsole MJ, Yu C, Hou L, Dai Q. Ca:Mg Ratio, APOE Cytosine Modifications, and Cognitive Function: Results from a Randomized Trial. J Alzheimers Dis. 2020;75(1):85-98. doi: 10.3233/JAD-191223.</citation>
    <PMID>32280092</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Qi Dai</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

